Six weeks ago, the FDA quietly closed one of the longest-running regulatory uncertainties in modern outpatient medicine. On April 23, 2026, twelve clinically meaningful peptides — including BPC-157, TB-500 (Thymosin Beta-4), CJC-1295, and Ipamorelin — were removed from the FDA's Category 2 restricted compounding list. Compounding through licensed 503A and 503B pharmacies, which had been functionally restricted for years, is once again available in the legal mainstream.
If you've followed peptides at all over the last 18 months, you've watched the conversation get louder, weirder, and more confusing. Patients have asked me three questions repeatedly: Are these things legal? Are they safe? And how do I get them without ending up in the gray market? The April 23 reclassification doesn't answer all three at once, but it changes the first one in a way that matters. Here is the plain-English version.
What actually changed on April 23
For the past several years, FDA's Pharmacy Compounding Advisory Committee (PCAC) had placed certain peptides on Category 2 — a status that, in practical terms, made compounding pharmacies unwilling to prepare them under either Section 503A (traditional patient-specific compounding) or 503B (registered outsourcing). Following a public review process and a February 27, 2026 announcement from HHS, twelve peptides came off Category 2 effective April 23.
That includes the workhorses of physician-led peptide medicine:
- BPC-157 — body protective compound, studied for tendon and ligament repair, gut healing, and inflammation.
- TB-500 (Thymosin Beta-4) — supports cell migration and fascial repair; the natural pair to BPC-157.
- CJC-1295 and Ipamorelin — the GHRH analog and selective GH secretagogue that, together, prompt physiologic growth-hormone release.
- And several other clinically relevant entries, with formal PCAC review scheduled for July 23–24, 2026.
What didn't change
Reclassification is not the same as FDA approval. The peptides removed from Category 2 are still not FDA-approved drugs in the way that, say, semaglutide or tesamorelin are. They are prescription therapeutics that are now legal to compound through licensed pharmacies — provided there's a valid prescription, an evaluation, an indication, and physician oversight. None of that infrastructure went away. None of it should.
"What changed is the lane. The standard for using these well — physician evaluation, documented sourcing, defined monitoring — is exactly what it was on April 22."
The other thing that didn't change: tesamorelin. Tesamorelin has long been FDA-approved for HIV-associated lipodystrophy and is dispensed under standard prescription. Its place in our visceral-fat protocol has been stable through this whole regulatory cycle. The April reclassification simply makes the rest of the menu — the peptides that had been hardest to access through compliant channels — available again.
What this means if you've been considering peptide therapy
For most patients I see, three things matter most:
- You no longer need to choose between waiting and going gray-market. Compliant compounding for BPC-157, TB-500, CJC-1295, and Ipamorelin is back. That removes the perverse incentive that pushed patients toward online "research peptides" of unknown sterility, identity, and potency.
- Sourcing is still the question that matters most. A compounded peptide is only as safe as the pharmacy that prepares it. A reputable 503A pharmacy can name its USP-grade APIs, its sterility testing, and its inspection history. So can a 503B. A questionable online vendor cannot.
- Monitoring still belongs to the physician, not the patient. Each peptide carries a baseline-and-follow-up plan: tesamorelin patients get IGF-1, glucose, and DEXA review; GH-secretagogue patients get IGF-1 and HbA1c review; NAD+ patients get hepatic and energy-marker review. Skipping that step is what separates therapeutic peptide use from the wellness-fad version.
The Limitless position, in one paragraph
Compounded peptides are real medicine when used correctly: a documented indication, a licensed pharmacy of origin, a written prescription, an informed-consent document, a defined monitoring plan, and a stop point. We do not stock retail peptides, sell at the front desk, or refer to online vendors. Every peptide a Limitless patient receives originates from a state-licensed 503A or FDA-registered 503B pharmacy under prescription written by me. That standard didn't change on April 23. The lane it operates in did.
What's next: the July PCAC review
The April 23 reclassification was the procedural step. The substantive review is scheduled for the July 23–24, 2026 PCAC meeting, where the committee will weigh formal status for these peptides under 503A and 503B compounding rules. The most likely outcome — though no committee outcome is guaranteed — is continued legal access through licensed compounding with structured monitoring expectations. We'll publish a follow-up note once the meeting concludes.
If you've been waiting for the regulatory picture to settle before considering peptide therapy, the current environment is the most stable it's been in three years. If you've been doing it without a physician — through a vendor, a clinic-in-a-box, or a friend — this is a good moment to bring it back into the medical lane.